Lista de obras - Eline Menu - Dominio Público Uruguay

A distinct metabolic response characterizes sensitivity to EZH2 inhibition in multiple myeloma

artículo científico publicado en 2021

A novel therapeutic combination using PD 0332991 and bortezomib: study in the 5T33MM myeloma model.

artículo científico publicado en 2008

AXL Receptor Tyrosine Kinase as a Therapeutic Target in Hematological Malignancies: Focus on Multiple Myeloma

artículo científico publicado en 2019

Angiogenic switch during 5T2MM murine myeloma tumorigenesis: role of CD45 heterogeneity.

artículo científico publicado en 2003

Bone marrow fibroblasts parallel multiple myeloma progression in patients and mice: in vitro and in vivo studies.

artículo científico publicado en 2013

Bone marrow stromal cell-derived exosomes as communicators in drug resistance in multiple myeloma cells.

artículo científico publicado en 2014

Bortezomib alone or in combination with the histone deacetylase inhibitor JNJ-26481585: effect on myeloma bone disease in the 5T2MM murine model of myeloma.

artículo científico publicado en 2009

Both mucosal-associated invariant and natural killer T-cell deficiency in multiple myeloma can be countered by PD-1 inhibition

artículo científico publicado en 2017

Cancer associated fibroblasts and tumor growth: focus on multiple myeloma

artículo científico publicado en 2014

Dll1/Notch activation accelerates multiple myeloma disease development by promoting CD138+ MM-cell proliferation.

artículo científico publicado en 2011

Does an NKT-cell-based immunotherapeutic approach have a future in multiple myeloma?

artículo científico publicado en 2016

Epigenetic modulating agents as a new therapeutic approach in multiple myeloma

artículo científico publicado en 2013

Epigenetic silencing of the tetraspanin CD9 during disease progression in multiple myeloma cells and correlation with survival.

artículo científico publicado en 2008

Exosomes play a role in multiple myeloma bone disease and tumor development by targeting osteoclasts and osteoblasts

article

Experimental African trypanosome infection suppresses the development of multiple myeloma in mice by inducing intrinsic apoptosis of malignant plasma cells.

artículo científico publicado en 2017

Extracellular S100A9 Protein in Bone Marrow Supports Multiple Myeloma Survival by Stimulating Angiogenesis and Cytokine Secretion.

artículo científico publicado en 2017

Extracellular vesicle cross-talk in the bone marrow microenvironment: implications in multiple myeloma

artículo científico publicado en 2016

Halting pro-survival autophagy by TGFβ inhibition in bone marrow fibroblasts overcomes bortezomib resistance in multiple myeloma patients.

artículo científico publicado en 2015

Histone deacetylase inhibitors in multiple myeloma

artículo científico publicado en 2009

IGF-1 suppresses Bim expression in multiple myeloma via epigenetic and posttranslational mechanisms.

artículo científico publicado en 2010

Imaging and radioimmunotherapy of multiple myeloma with anti-idiotypic Nanobodies

artículo científico publicado en 2013

Impaired osteogenic differentiation of mesenchymal stem cells derived from multiple myeloma patients is associated with a blockade in the deactivation of the Notch signaling pathway

artículo científico publicado en 2012

In vivo treatment with epigenetic modulating agents induces transcriptional alterations associated with prognosis and immunomodulation in multiple myeloma.

artículo científico publicado en 2015

Induction of miR-146a by multiple myeloma cells in mesenchymal stromal cells stimulates their pro-tumoral activity

artículo científico publicado en 2016

Inhibiting the IGF-1 receptor tyrosine kinase with the cyclolignan PPP: an in vitro and in vivo study in the 5T33MM mouse model.

artículo científico publicado en 2005

Inhibiting the anaphase promoting complex/cyclosome induces a metaphase arrest and cell death in multiple myeloma cells

artículo científico publicado en 2015

Inhibition of VEGF secretion and experimental choroidal neovascularization by picropodophyllin (PPP), an inhibitor of the insulin-like growth factor-1 receptor

artículo científico publicado en 2008

Inhibition of VEGF secretion and experimental choroidal neovascularization by picropodophyllin (PPP), an inhibitor of the insulin-like growth factor-1 receptor

artículo científico publicado en 2008

Inhibition of p38alpha mitogen-activated protein kinase prevents the development of osteolytic bone disease, reduces tumor burden, and increases survival in murine models of multiple myeloma

artículo científico publicado en 2007

Leptin receptor antagonism of iNKT cell function: a novel strategy to combat multiple myeloma

artículo científico publicado en 2017

Loss of RASSF4 expression in multiple myeloma promotes RAS-driven malignant progression.

artículo científico publicado en 2017

Maternal embryonic leucine zipper kinase is a novel target for diffuse large B cell lymphoma and mantle cell lymphoma

scientific article published on 18 November 2019

Mechanisms involved in the differential bone marrow homing of CD45 subsets in 5T murine models of myeloma.

artículo científico publicado en 2002

Metabolic Features of Multiple Myeloma.

artículo científico publicado en 2018

Molecular mechanisms, current management and next generation therapy in myeloma bone disease.

artículo científico publicado en 2017

Multiple myeloma exosomes establish a favourable bone marrow microenvironment with enhanced angiogenesis and immunosuppression

artículo científico publicado en 2016

Multiple myeloma induces Mcl-1 expression and survival of myeloid-derived suppressor cells

artículo científico publicado en 2015

Multiple myeloma induces the immunosuppressive capacity of distinct myeloid-derived suppressor cell subpopulations in the bone marrow

scientific article published on 23 April 2012

Myeloid-derived suppressor cells as therapeutic target in hematological malignancies

artículo científico publicado en 2014

Novel strategies to target the ubiquitin proteasome system in multiple myeloma

artículo científico publicado en 2016

Oral picropodophyllin (PPP) is well tolerated in vivo and inhibits IGF-1R expression and growth of uveal melanoma

scientific article published on 01 June 2008

Oral picropodophyllin (PPP) is well tolerated in vivo and inhibits IGF-1R expression and growth of uveal melanoma.

artículo científico publicado en 2008

Preclinical evaluation of invariant natural killer T cells in the 5T33 multiple myeloma model

artículo científico publicado en 2013

Role of CCR1 and CCR5 in homing and growth of multiple myeloma and in the development of osteolytic lesions: a study in the 5TMM model

artículo científico publicado en 2006

SRC kinase inhibition with saracatinib limits the development of osteolytic bone disease in multiple myeloma.

artículo científico publicado en 2016

Signal transducer and activator of transcription 3 in myeloid-derived suppressor cells: an opportunity for cancer therapy

artículo científico publicado en 2016

Specific roles for the PI3K and the MEK-ERK pathway in IGF-1-stimulated chemotaxis, VEGF secretion and proliferation of multiple myeloma cells: study in the 5T33MM model.

artículo científico publicado en 2004

Stimulation of invariant natural killer T cells by α-Galactosylceramide activates the JAK-STAT pathway in endothelial cells and reduces angiogenesis in the 5T33 multiple myeloma model

artículo científico publicado en 2014

Synergistic induction of apoptosis in multiple myeloma cells by bortezomib and hypoxia-activated prodrug TH-302, in vivo and in vitro.

artículo científico publicado en 2013

The F-actin content of multiple myeloma cells as a measure of their migration.

artículo científico publicado en 2002

The HDAC inhibitor LBH589 enhances the antimyeloma effects of the IGF-1RTK inhibitor picropodophyllin.

artículo científico publicado en 2012

The IGF-1 receptor inhibitor picropodophyllin potentiates the anti-myeloma activity of a BH3-mimetic

artículo científico publicado en 2014

The bone marrow microenvironment enhances multiple myeloma progression by exosome-mediated activation of myeloid-derived suppressor cells.

artículo científico publicado en 2015

The effects of JNJ-26481585, a novel hydroxamate-based histone deacetylase inhibitor, on the development of multiple myeloma in the 5T2MM and 5T33MM murine models.

artículo científico publicado en 2009

The genetic landscape of 5T models for multiple myeloma

artículo científico publicado en 2018

The insulin-like growth factor system in multiple myeloma: diagnostic and therapeutic potential

artículo científico publicado en 2016

The involvement of stromal derived factor 1alpha in homing and progression of multiple myeloma in the 5TMM model.

artículo científico publicado en 2006

The microenvironment and molecular biology of the multiple myeloma tumor.

scientific article published on January 2011

The new anti-actin agent dihydrohalichondramide reveals fenestrae-forming centers in hepatic endothelial cells

artículo científico publicado en 2002

The role of DNA damage and repair in decitabine-mediated apoptosis in multiple myeloma

artículo científico publicado en 2014

The therapeutic potential of cell cycle targeting in multiple myeloma

artículo científico publicado en 2017

Thymosin β4 has tumor suppressive effects and its decreased expression results in poor prognosis and decreased survival in multiple myeloma

artículo científico publicado en 2009

Tumor-initiating capacity of CD138- and CD138+ tumor cells in the 5T33 multiple myeloma model

artículo científico publicado en 2012

Tumour-associated macrophage-mediated survival of myeloma cells through STAT3 activation.

artículo científico publicado en 2016

Understanding the hypoxic niche of multiple myeloma: therapeutic implications and contributions of mouse models.

artículo científico publicado en 2012

Lista de obras de Eline Menu

A distinct metabolic response characterizes sensitivity to EZH2 inhibition in multiple myeloma

A novel therapeutic combination using PD 0332991 and bortezomib: study in the 5T33MM myeloma model.

AXL Receptor Tyrosine Kinase as a Therapeutic Target in Hematological Malignancies: Focus on Multiple Myeloma

Angiogenic switch during 5T2MM murine myeloma tumorigenesis: role of CD45 heterogeneity.

Bone marrow fibroblasts parallel multiple myeloma progression in patients and mice: in vitro and in vivo studies.

Bone marrow stromal cell-derived exosomes as communicators in drug resistance in multiple myeloma cells.

Bortezomib alone or in combination with the histone deacetylase inhibitor JNJ-26481585: effect on myeloma bone disease in the 5T2MM murine model of myeloma.

Both mucosal-associated invariant and natural killer T-cell deficiency in multiple myeloma can be countered by PD-1 inhibition

Cancer associated fibroblasts and tumor growth: focus on multiple myeloma

Dll1/Notch activation accelerates multiple myeloma disease development by promoting CD138+ MM-cell proliferation.

Does an NKT-cell-based immunotherapeutic approach have a future in multiple myeloma?

Epigenetic modulating agents as a new therapeutic approach in multiple myeloma

Epigenetic silencing of the tetraspanin CD9 during disease progression in multiple myeloma cells and correlation with survival.

Exosomes play a role in multiple myeloma bone disease and tumor development by targeting osteoclasts and osteoblasts

Experimental African trypanosome infection suppresses the development of multiple myeloma in mice by inducing intrinsic apoptosis of malignant plasma cells.

Extracellular S100A9 Protein in Bone Marrow Supports Multiple Myeloma Survival by Stimulating Angiogenesis and Cytokine Secretion.

Extracellular vesicle cross-talk in the bone marrow microenvironment: implications in multiple myeloma

Halting pro-survival autophagy by TGFβ inhibition in bone marrow fibroblasts overcomes bortezomib resistance in multiple myeloma patients.

Histone deacetylase inhibitors in multiple myeloma

IGF-1 suppresses Bim expression in multiple myeloma via epigenetic and posttranslational mechanisms.

Imaging and radioimmunotherapy of multiple myeloma with anti-idiotypic Nanobodies

Impaired osteogenic differentiation of mesenchymal stem cells derived from multiple myeloma patients is associated with a blockade in the deactivation of the Notch signaling pathway

In vivo treatment with epigenetic modulating agents induces transcriptional alterations associated with prognosis and immunomodulation in multiple myeloma.

Induction of miR-146a by multiple myeloma cells in mesenchymal stromal cells stimulates their pro-tumoral activity

Inhibiting the IGF-1 receptor tyrosine kinase with the cyclolignan PPP: an in vitro and in vivo study in the 5T33MM mouse model.

Inhibiting the anaphase promoting complex/cyclosome induces a metaphase arrest and cell death in multiple myeloma cells

Inhibition of VEGF secretion and experimental choroidal neovascularization by picropodophyllin (PPP), an inhibitor of the insulin-like growth factor-1 receptor

Inhibition of VEGF secretion and experimental choroidal neovascularization by picropodophyllin (PPP), an inhibitor of the insulin-like growth factor-1 receptor

Inhibition of p38alpha mitogen-activated protein kinase prevents the development of osteolytic bone disease, reduces tumor burden, and increases survival in murine models of multiple myeloma

Leptin receptor antagonism of iNKT cell function: a novel strategy to combat multiple myeloma

Loss of RASSF4 expression in multiple myeloma promotes RAS-driven malignant progression.

Maternal embryonic leucine zipper kinase is a novel target for diffuse large B cell lymphoma and mantle cell lymphoma

Mechanisms involved in the differential bone marrow homing of CD45 subsets in 5T murine models of myeloma.

Metabolic Features of Multiple Myeloma.

Molecular mechanisms, current management and next generation therapy in myeloma bone disease.

Multiple myeloma exosomes establish a favourable bone marrow microenvironment with enhanced angiogenesis and immunosuppression

Multiple myeloma induces Mcl-1 expression and survival of myeloid-derived suppressor cells

Multiple myeloma induces the immunosuppressive capacity of distinct myeloid-derived suppressor cell subpopulations in the bone marrow

Myeloid-derived suppressor cells as therapeutic target in hematological malignancies

Novel strategies to target the ubiquitin proteasome system in multiple myeloma

Oral picropodophyllin (PPP) is well tolerated in vivo and inhibits IGF-1R expression and growth of uveal melanoma

Oral picropodophyllin (PPP) is well tolerated in vivo and inhibits IGF-1R expression and growth of uveal melanoma.

Preclinical evaluation of invariant natural killer T cells in the 5T33 multiple myeloma model

Role of CCR1 and CCR5 in homing and growth of multiple myeloma and in the development of osteolytic lesions: a study in the 5TMM model

SRC kinase inhibition with saracatinib limits the development of osteolytic bone disease in multiple myeloma.

Signal transducer and activator of transcription 3 in myeloid-derived suppressor cells: an opportunity for cancer therapy

Specific roles for the PI3K and the MEK-ERK pathway in IGF-1-stimulated chemotaxis, VEGF secretion and proliferation of multiple myeloma cells: study in the 5T33MM model.

Stimulation of invariant natural killer T cells by α-Galactosylceramide activates the JAK-STAT pathway in endothelial cells and reduces angiogenesis in the 5T33 multiple myeloma model

Synergistic induction of apoptosis in multiple myeloma cells by bortezomib and hypoxia-activated prodrug TH-302, in vivo and in vitro.

The F-actin content of multiple myeloma cells as a measure of their migration.

The HDAC inhibitor LBH589 enhances the antimyeloma effects of the IGF-1RTK inhibitor picropodophyllin.

The IGF-1 receptor inhibitor picropodophyllin potentiates the anti-myeloma activity of a BH3-mimetic

The bone marrow microenvironment enhances multiple myeloma progression by exosome-mediated activation of myeloid-derived suppressor cells.

The effects of JNJ-26481585, a novel hydroxamate-based histone deacetylase inhibitor, on the development of multiple myeloma in the 5T2MM and 5T33MM murine models.

The genetic landscape of 5T models for multiple myeloma

The insulin-like growth factor system in multiple myeloma: diagnostic and therapeutic potential

The involvement of stromal derived factor 1alpha in homing and progression of multiple myeloma in the 5TMM model.

The microenvironment and molecular biology of the multiple myeloma tumor.

The new anti-actin agent dihydrohalichondramide reveals fenestrae-forming centers in hepatic endothelial cells

The role of DNA damage and repair in decitabine-mediated apoptosis in multiple myeloma

The therapeutic potential of cell cycle targeting in multiple myeloma

Thymosin β4 has tumor suppressive effects and its decreased expression results in poor prognosis and decreased survival in multiple myeloma

Tumor-initiating capacity of CD138- and CD138+ tumor cells in the 5T33 multiple myeloma model

Tumour-associated macrophage-mediated survival of myeloma cells through STAT3 activation.

Understanding the hypoxic niche of multiple myeloma: therapeutic implications and contributions of mouse models.